The Qt Company Joins AdvaMed and MassMEDIC to Guide Policy and Technology Innovation in the Medical Device Industry

The Qt Company (HEX: QTCOM) today announced it will become a member of leading medical technology professional organizations AdvaMed and MassMEDIC, stepping into the integral role of industry advisor and enabler of technology innovation. In this role, Qt will influence the direction of the standards and regulations that govern the medical device industry on a global scale, and will help introduce new medical device technology advancements.

The Advanced Medical Technology Association (AdvaMed) is a trade association that leads the effort to advance medical technology to achieve healthier lives and healthier economies around the world. The Massachusetts Medical Device Industry Council (MassMEDIC) is an organization of medical device manufacturers, suppliers and associated non-profit groups in Massachusetts and the surrounding region. AdvaMed and MassMEDIC work closely with national and international organizations such as the U.S. Food and Drug Administration (FDA) and European Union (EU) to advocate and promote policies directly from the medical community.

"Like many other industries, the medical sector must comply with multiple regulations, guidelines and policies, and groups like ours aim to reflect the unique interests of the medical device industry at state, federal, and global levels," said Thomas Sommer, president of the MassMEDIC Association. "MassMEDIC serves as a forum for the Northeast region's leading medical device manufacturers and suppliers to discuss and challenge key policies and trends impacting the sector, and we're delighted to welcome Qt to the fold. We're looking forward to working with Qt to support the development of innovative medical technologies and better healthcare delivery solutions."

New developments and the continued rise of Internet of Medical Things (IoMT) technologies have created more challenges than ever for medical device developers, bringing issues such as data security and integrity to the forefront. Qt will address these innovations and technologies that gave rise to new industry requirements and standards at this year's MedTech Conference (organized by AdvaMed), as well as the Qt World Summit. At both events, Qt will share how it is helping the industry meet and overcome the challenges at hand, in order to bring the latest medical device innovations to market.

"The medical industry is evolving rapidly, and our goal is to help influence the direction of technology innovation and the standards and requirements that govern the sector, both in our backyard and across the globe," said Roger Mazzella, Senior Product Manager for The Qt Company. "With our membership in AdvaMed and MassMEDIC, as well as the various working groups in which we participate, we are collaborating with our peers to help medical device manufacturers deliver the best possible health outcomes to consumers all over the world."

For more information regarding the 2017 MedTech Conference by AdvaMed, please visit: https://www.advamed.org/events/medtech-conference

For more information regarding the 2017 Qt World Summit, please visit: http://www.qtworldsummit.com/

About The Qt Company
The Qt Company develops and delivers the Qt development framework under commercial and open source licenses. We enable a single software code across all operating systems, platforms and screen types, from desktops and embedded systems to wearables and mobile devices. Qt is used by approximately one million developers worldwide and is the leading independent technology behind millions of devices and applications. Qt is the platform of choice for in-vehicle systems, medical devices, industrial automation devices, and other business critical application manufacturers, and is used by leading global players in more than 70 industries. The Qt Company is owned by the Qt Group, which operates in China, Finland, Germany, Japan, Korea, Norway, Russia and USA with more than 200 employees worldwide. The Qt Group is headquartered in Espoo, Finland and is listed on Nasdaq Helsinki Stock Exchange. The company's net sales in year 2016 totaled 32,4 MEUR. To learn more visit http://qt.io

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.